28th Oct 2019 16:16
(Alliance News) - AstraZeneca PLC said Monday its Imfinzi and Imfinzi plus tremelimumab trial has seen "positive" results, with the trial meeting its primary endpoint.
The progression-free survival trial showed a "statistically significant and clinically meaningful" improvement in patients treated with the combination of Imfinzi and a broad choice of five standard-of-care platinum-based chemotherapy options versus chemotherapy alone.
Astra said the Phase III Poseidon trial was looking into disease progression for first-line treatment of stage IV non-small cell lung cancer.
"The triple combination of Imfinzi plus tremelimumab and chemotherapy also demonstrated a statistically significant and clinically meaningful progression-free survival improvement versus chemotherapy alone as a key secondary endpoint," Astra added.
The pharma giant continued: "The safety and tolerability of Imfinzi was consistent with its known safety profile. The triple combination delivered a broadly similar safety profile to the Imfinzi and chemotherapy combination and did not result in increased discontinuation of therapy."
Oncology Research & Development Executive Vice President JoseÌ Baselga added: "The Poseidon trial provides evidence of the efficacy of Imfinzi in patients with Stage IV non-small cell lung cancer. Clinical benefit was observed in a trial population that included a high proportion of patients with squamous disease and multiple choices of chemotherapy regimens.
"Additionally, the potential to add tremelimumab to Imfinzi and chemotherapy may present an important treatment approach in this challenging setting, especially taking into consideration the favourable safety profile."
The trial will continue to assess the additional primary endpoint of overall survival with data expected in 2020, Astra said.
Imfinzi is also being tested in Stage IV non-small cell lung cancer as monotherapy in the Phase III Pearl trial, and in earlier stages of disease as part of an extensive Immuno-Oncology programme in lung cancer.
Imfinzi is currently approved for non-small cell lung cancer treatment in 53 countries, including the US, Japan and across the EU, based on the Phase III Pacific trial.
Shares in AstraZeneca were 1.1% higher in London on Monday afternoon at 7,465.00 pence each.
By Paul McGowan; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca